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• Abnormal elevation in PAP,result of: 
- left heart failure,  
- pulmonary parenchymal disease  
- pulmonary vascular disease,  
- pulmonary thromboembolism,  
- or a combination of these factors. 
• generally is a feature of advanced disease. 
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Pulmonary Hypertension Overview 
• Defined as:  
-mean PAP > 25mm Hg at rest  
-or >30mm Hg with exertion 
 
• Categorized by WHO in 1973 into just 
primary PH vs. secondary PH 
• In 1998, WHO reclassified disease  
   into 5 specific sub-categories  
   based on specific disease process. 
NEW CLASSIFICATION 
• 1-PAH;  idiopathic, familial, dis. & drug associated, 
PVOD & PCH, persistant new born PH. 
• 2-PH in left heart dis. 
• 3-PH in respiratory dis. 
• 4-PH in chronic thromboembolic dis. 
• 5-PH in miscellaneous condition. 
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• Etiology underlying the PH be clearly 
determined before starting treatment. 
 
• PH is the most common cause of cor 
pulmonale.  
 
• Advanced cor pulmonale is associated with 
the development of RV failure. 
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Pathophysiology 
• The RV responds to an increase in resistance 
within the pulmonary circulation by increasing 
RVSP to preserve CO.  
• Over time, chronic changes occur in the pulmonary 
circulation, result in progressive remodeling of the 
vasculature, can sustain PH, even if the initiating 
factor is removed. 
• Onset of clinical RV failure, usually manifest by 
peripheral edema, associated with a poor outcome. 
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Diagnosis 
 
• Symptom: 
• Most common symptom is DOE. 
• Other common symptoms:  
-fatigue,  
-CP that may represent RV ischemia,  
-syncope,  
-near syncope,  
-and peripheral edema. 
 8 
• Physical examination:  
-increased JVP,  
-reduced carotid pulse,  
-palpable RV impulse.  
-Increased pulmonic component of the S2,  
-right-sided S4,  
-and tricuspid regurgitation.  
-Peripheral cyanosis and/or edema occur in later stages.  
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Chest X-Ray  
The chest x-ray generally shows enlarged central pulmonary 
arteries. The lung fields may or may not reveal other 
pathology. One of the things the physician will check is whether 
the right side of the heart is enlarged.  
 
ECG demonstrating the changes of RVH(long arrow) with strain in a patient with PPH. 
Right axis deviation (short arrow), increased P-wave amplitude in lead II (black 
arrowhead), and incomplete RBBB(white arrowhead) are highly specific but lack 
sensitivity for the detection of RVH. 
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• Pulmonary function tests are helpful in 
documenting underlying obstructive 
airways disease, 
• High-resolution chest CT is preferred to 
diagnose restrictive lung disease.  
• Hypoxemia and an abnormal diffusing 
capacity for carbon monoxide are common 
features of PH of many causes.  
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A 
A 
A perfusion lung scan is almost always abnormal in 
patients with thromboembolic PH. 

•  Laboratory tests should include  
antinuclear antibody and HIV testing.  
 
• Because of the high frequency of thyroid 
abnormalities in idiopathic PH,  
TSH level be determined periodically. 
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An algorithm 
for the workup 
of a patient 
with 
unexplained 
pulmonary 
hypertension. 
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Cardiac Catheterization 
• For accurate measurement of: 
 PAP, CO, and LV filling pressure, 
as well as for exclusion of an 
underlying cardiac shunt. 
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Pulmonary Angiogram 
Used to measure circulation in the lungs and to visualize clots in the lung 
on x-rays. The test involves insertion of a thin catheter into the pulmonary 
artery through which an iodine dye is injected. 
Image of any blood clots present in the lung can be observed and 
circulation of blood through lung’s blood vessels can be tracked. 
 

• Patients with PH should undergo drug testing 
with a short-acting pulmonary vasodilator at the 
time of cardiac catheterization to determine the 
extent of pulmonary vasodilator reactivity . 
 
•  Inhaled nitric oxide, intravenous adenosine, and 
intravenous epoprostenol appear to have 
comparable effects in reducing PAP acutely. 
 
•  Patients who respond can often be treated with 
calcium channel blockers and have a more 
favorable prognosis. 
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An algorithm 
for the 
selection of 
optimal drug 
treatment of 
a patient with 
pulmonary 
arterial 
hypertension. 
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1. PAH 
• A-Idiopathic PAH 
• B-Familial PAH 
• C-Associated with: 
• Connective tissue disease 
• CHD (shunts) 
• Portal hypertension 
• HIV infection 
• Sickle cell disease 
• Drugs and toxins 
• Other 
• D-Associated with significant 
venous or capillary 
involvement(PVOD,PCH) 
• E-Persistent PH of  the 
newborn 
 
2. PH associated with left heart  
disease 
 
3. PH associated with respiratory 
disease 
• COPD 
• Interstitial lung diseases 
 
4. PH due to chronic thrombotic 
and/or embolic disease 
 
5. Miscellaneous 
classification 
1. Simonneau G et al. JACC 2004 
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 GROUP 1 
Pulmonary Arterial Hypertension 
 
• There are many causes of pulmonary 
arterial hypertension (PAH). 
•  Patients with PAH share a common 
histopathology characterized by 
- medial hypertrophy,  
- eccentric and concentric intimal fibrosis,  
- recanalized thrombi appearing as fibrous webs,  
- and plexiform lesions. 
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Pathobiology 
• Abnormalities in molecular pathways 
regulating the pulmonary vascular 
endothelial and smooth-muscle cells have 
been described as underlying PAH.  
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• These include: 
  
-   inhibition of the voltage-regulated K. channel, 
- mutations in the bone morphogenetic protein-2 
receptor,  
- increased serotonin uptake in the SMCs,  
- increased angiopoietin expression in the SMCs,  
- and excessive thrombin deposition related to a 
procoagulant state. 
 
-  As a result loss of apoptosis of the SMCs, allowing 
their proliferation, and emergence of apoptosis-
resistant endothelial cells which can obliterate the 
vascular lumen. 
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A-Idiopathic Pulmonary Arterial Hypertension 
• PPH is uncommon, with an estimated 
incidence of two cases per million.  
 
• There is a strong female predominance, 
with most patients presenting in the fourth 
and fifth decades, although the age range 
is from infancy to >60 years. 
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• B-Familial IPAH accounts for up to 20% of 
cases of IPAH and is characterized by 
autosomal dominant inheritance, variable 
age of onset, and incomplete penetrance. 
 
• The clinical and pathologic features of 
familial and sporadic IPAH are identical.  
 
34 
• Heterozygous germline mutations that 
involve the gene coding the type II 
bone morphogenetic protein receptor 
(BMPR II), a member of the 
transforming growth factor (TGF) 
superfamily, appear to account for 
most cases of familial IPAH. 
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Mechanistic pathways promoting pulmonary arterial hypertension (PAH). External 
stimuli, such as hypoxia or anorexigens, can stimulate a serotoninergic pathway which, 
in concert with internal stimuli involving the TGF-ᵝ receptor pathway can produce PAH. 
5-HT2B, serotonin receptor; 5-HTT, serotonin transporter;  
TGF-ᵝ, transforming growth factor ᵝ ; TIE2, angiopoietein-1 receptor;  
BMPR1A, bone morphogenetic protein receptor 1A;  
mBMPR2, mutant form of bone morphogenetic protein receptor 2;  
mALK1, activin-receptor-like kinase. 
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Natural History 
• The natural history of IPAH is uncertain,  
• because the predominant symptom is dyspnea, 
with insidious onset, the disease is typically 
diagnosed late in its course. 
 
•  Prior to current therapies, a mean survival of 
2–3 years from the time of diagnosis was 
reported.  
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• Functional class remains a strong 
predictor of survival, with NYHA FC IV 
having a mean survival of <6 months.  
 
• The cause of death is usually RV failure, 
manifest by progressive hypoxemia, 
tachycardia, hypotension, and edema. 
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 Treatment 
• PAH refers to a variety of diseases, which 
includes idiopathic (I)PAH.  
• Several treatments for PAH have approved. 
• 1- patients should be cautioned against 
participating in activities that demand increased 
physical stress.  
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• 2-Diuretic therapy relieves peripheral 
edema and may be useful in reducing RV 
volume overload in the presence of TR. 
•  3-Resting and exercise pulse oximetry 
should be obtained, as O2 
supplementation helps to alleviate 
dyspnea and RV ischemia in patients 
whose arterial O2 saturation is reduced. 
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• 4- Anticoagulant therapy for all patients with 
PAH based on retrospective and prospective 
studies demonstrating that warfarin increases 
survival of PAH patients.  
 
• The dose of warfarin is generally titrated to 
achieve an INR of 2–3 times control. 
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5-Calcium Channel Blockers 
• Patients who have substantial reductions in 
PAP in response to short-acting vasodilators at 
cardiac catheterization (a fall in mean PAP 10 mmHg 
and a final mean pressure <40 mmHg) should be treated 
initially with calcium channel blockers. 
•  Typically, patients require high doses  
   (e.g., nifedipine, 240 mg/d, or amlodipine, 20 mg/d).  
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• Patients who respond favorably usually 
have dramatic reductions in PAP and PVR 
associated with improved symptoms, 
regression of RVH, and improved survival 
now documented to exceed 20 years. 
•  However, <20% of patients respond to 
calcium channel blockers in the long term.  
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• These drugs should not be given 
to patients who are unresponsive, 
as they can result in hypotension, 
hypoxemia, tachycardia, and 
worsening right heart failure.  
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6- Current  therapies target multiple growth factor pathways 
that appear to be involved in the pathogenesis of PAH. 
45 
Endothelin Receptor Antagonists 
• The nonselective endothelin receptor 
antagonist bosentan is an approved 
treatment of PAH for NYHA FC III and IV.  
• Improve symptoms and exercise tolerance 
(increase in 6-min walking distance).  
• Initiated at 62.5 mg bid for the first month and 
then increased to 125 mg bid. 
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Phosphodiesterase-5 Inhibitors 
• Sildenafil, a phosphodiesterase-5 inhibitor, 
is approved for the treatment of PAH in 
NYHA FC II and III. 
• Phosphodiesterase-5 is responsible for the 
hydrolysis of cyclic GMP in pulmonary 
vascular smooth muscle, the mediator 
through which nitric oxide lowers PAP and 
inhibits pulmonary vascular growth.  
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Prostacyclins 
• Iloprost, a prostacyclin analogue, is approved 
via inhalation for PAH in NYHA FC III and IV. 
•  improve symptoms and exercise tolerance.  
• Therapy can be given at either 2.5 or 5 mcg per 
inhalation treatment. (by a dedicated nebulizer). 
•  The most common side effects are flushing and 
cough. Drug is very short half-life (<30 min)  
(administer treatments as often as every 2 h). 
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• Epoprostenol  is approved for the treatment of 
PAH in NYHA FC III or IV.  
• Clinical trials have demonstrated an improvement 
in symptoms, exercise tolerance, and survival even 
if no acute hemodynamic response to drug 
challenge occurs.  
• Administered IV and requires placement of a 
permanent CVP catheter and infusion through an 
ambulatory infusion pump.  
• Side effects include flushing, jaw pain, and 
diarrhea; generally tolerated by most patients. 
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• Treprostinil, an analogue of epoprostenol, is approved for 
patients with PAH in NYHA FC II–IV. 
•  Treprostinil has a longer half-life than epoprostenol (4 h), 
is stable at room temperature, and may be given IV or 
subcutaneously through a small infusion pump that was 
originally developed for insulin. 
•  Demonstrated an improvement in symptoms and exercise 
capacity.  
• The major problem with the subcutaneous administration 
has been local pain at the infusion site, which has caused 
many patients to discontinue therapy.  
 
• Side effects are similar to those seen with epoprostenol. 
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• Favorable properties of prostacyclins include 
vasodilation, platelet inhibition, inhibition of 
vascular smooth-muscle growth, and inotropic 
effects. 
 
• Although most clinical trials have focused on 
patients with advanced symptoms, it is 
recommended that every patient diagnosed 
with PAH be treated. 
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• In the trials using bosentan, sildenafil, and 
iloprost, full clinical benefit was generally 
manifest within the first 2 months of therapy. 
 
• Patients who fail to adequately improve 
should have the treatment discontinued and 
started on a different therapy. 
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Lung Transplantation 
• Lung transplantation is considered for 
patients who, while on an IV prostacyclin, 
continue to manifest RV HF.  
• Acceptable results have been achieved 
with heart-lung, bilateral lung, and single-
lung transplant.  
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C-Conditions Associated with PH 
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Collagen Vascular Disease 
• All of the collagen vascular diseases may be associated 
with PAH.  
• This complication occurs commonly with 
-CREST syndrome (calcinosis, Raynaud's phenomenon, 
esophageal involvement, sclerodactyly, and telangiectasia) 
- scleroderma,  
- less frequently in systemic lupus erythematosus,  
- Sjögren's syndrome,  
- dermatomyositis,  
- polymyositis,  
- and rheumatoid arthritis.  
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• Treatment of these patients is identical to that 
of patients with IPAH but is less effective. 
•  The treatment of the PH, however, does not 
affect the natural history of the underlying 
collagen vascular disease. 
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Congenital Systemic to Pulmonary Shunts 
• It is common for large post-tricuspid cardiac 
shunts (e.g., VSD,PDA) to produce severe PAH.  
• Less common, it may occur in pre-tricuspid 
shunts (e.g., ASD, anomalous pulmonary venous drainage). 
• with uncorrected shunts, the clinical features 
include hypoxemia and peripheral cyanosis, 
which worsen dramatically with exertion. 
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• PAH may occur years or even decades after 
surgical correction of these lesions, in which 
case there will be no associated right-to-left 
shunting.  
• These patients present similarly to patients with 
IPAH but tend to have better long-term survival.  
• The treatments are similar to those for IPAH. 
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Portal Hypertension 
• Portal hypertension is associated with PAH, 
but the mechanism remains unknown.  
• The etiology of ascites and edema can be 
confusing; can have both cardiac and 
hepatic causes.  
• Patients with mild PH who have a favorable 
response to epoprostenol have undergone 
successful liver transplantation with 
improvement of the pulmonary vascular dis. 
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Anorexigens 
• A causal relationship has been established 
between exposure to several anorexigens, 
including aminorex and the fenfluramines, and the 
development of PAH.  
• Often the PH will not develop until years after the 
last exposure.  
• Clinical features are identical to those of IPAH, the 
patients appear to be less responsive to medical 
treatments and have a poorer prognosis. 
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D-Pulmonary Venoocclusive Disease 
• Pulmonary venoocclusive disease is a rare 
and distinct pathologic entity found in <10% 
of patients who present with unexplained PH. 
  
• Histologically it is manifest by intimal 
proliferation and fibrosis of the 
intrapulmonary veins and venules, 
occasionally extending to the arteriolar bed. 
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•  The pulmonary venous obstruction explains the 
increase in PCWP observed in patients with 
advanced disease.  
• These patients may develop orthopnea that can 
mimic LV failure.  
• The therapy of this condition is not established. 
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D-Pulmonary Capillary Hemangiomatosis 
 
• A very rare form of PAH. 
  
• Histologically it is characterized by the 
presence of infiltrating thin-walled blood 
vessels throughout the pulmonary 
interstitium and walls of the pulmonary 
arteries and veins.  
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• Symptoms are usually those of IPAH but 
often with hemoptysis as a clinical feature.  
 
• The diagnosis can be made with 
pulmonary angiography.  
• The clinical course is usually one of 
progressive deterioration leading to death.  
• There is no established therapy. 
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GROUP II 
Pulmonary Venous Hypertension 
(PH associated with left heart  disease) 
 • PH occurs as a result of increased resistance to 
pulmonary venous drainage.  
• It is often associated with:  
-diastolic LV dysfunction;  
-diseases of pericard, or mitral or aortic valves; 
• or rare entities such as:  
-cor triatriatum,  
-left atrial myxoma,  
-extrinsic compression of the central pulmonary veins from 
fibrosing mediastinitis,  
and pulmonary venoocclusive disease.  
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• Microcirculatory lesions include  
-capillary congestion,  
-focal alveolar edema,  
-dilatation of the interstitial lymphatics.  
• Although these lesions are potentially 
reversible, regression may take years 
after the underlying cause is removed. 
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• In some patients pulmonary venous 
hypertension can produce severe 
elevations in PAP.  
• Clinically it may be confusing and appear as 
if two separate disease processes are 
occurring simultaneously.  
• The distinction is important, however, as 
treatments that are effective in PAH may 
make patients with pulmonary venous 
hypertension worse. 
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Left Ventricular Diastolic Dysfunction 
• PH as a result of LV diastolic failure is common but often 
unrecognized. 
•  It can occur with or without LV systolic failure.  
• The most common causes are: 
- hypertensive heart disease;  
- coronary artery disease;  
- impaired LV compliance related to age, diabetes, obesity, 
and hypoxemia.  
• Symptoms of orthopnea and PND are prominent.  
• Many patients improve considerably if LVEDP is lowered. 
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Mitral Valve Disease 
• MS and MR are important causes of PH.  
• These patients often have reactive 
pulmonary vasoconstriction resulting in 
marked elevations in PAP.  
• At cardiac catheterization, a pressure 
gradient between the pulmonary capillary 
wedge pressure and LV end-diastolic 
pressure is diagnostic of mitral stenosis. 
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• In patients with MS, corrective surgery of 
the mitral valve or mitral balloon 
valvuloplasty predictably results in a 
reduction in PAP and PVR. 
  
• MR, may not have as dramatic a response 
from surgery due to persistent elevations 
in LVEDP. 
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GROUP III 
PH Associated with Lung Disease and Hypoxemia 
• The mechanism of hypoxic pulmonary 
vasoconstriction involves the inhibition of 
potassium currents and membrane 
depolarization of pulmonary vascular 
smooth muscle.  
•  Increased calcium entry into the vascular 
smooth-muscle cells mediates hypoxic 
pulmonary vasoconstriction.  
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• Pulmonary vascular remodeling in 
response to chronic hypoxia mediated by: 
 
- reduction in nitric oxide production;  
- increase in endothelin 1;  
- increased expression of PDGF,  
- vascular endothelial growth factor,  
- and angiotensin II.  
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 • Chronic hypoxia rarely leads to an 
increase in the systolic PAP >50 mmHg.  
• Polycythemia in response to the 
hypoxemia is a characteristic finding.  
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• Hypoxia may also occur in conjunction 
with other causes of PH associated with 
more extensive vascular changes.  
• Patients with chronic hypoxia who have a 
marked elevation in PAP should be 
evaluated for other causes of the PH. 
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Chronic Obstructive Lung Disease 
• COLD is associated with mild PH in the advanced 
stages .  
• PH has been attributed to multiple factors: 
-hypoxic pulmonary vasoconstriction,  
-acidemia,  
-hypercapnia,  
-the mechanical effects of high lung volume on 
pulmonary vessels,  
-the loss of small vessels in the vascular bed,  
-and regions of emphysematous lung destruction. 
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• The presence of PH in COLD confers a 
worse outcome.  
• The only effective therapy is supplemental 
oxygen. 
• continuous oxygen therapy relieves some 
of the pulmonary vasoconstriction, relieves 
chronic ischemia throughout the systemic 
and pulmonary vascular beds, and 
improves survival.  
• Long-term oxygen therapy is indicated if the 
resting arterial PO2 <55 mmHg. 
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Interstitial Lung Disease 
 
• PH from interstitial lung disease is often associated 
with obliteration of the pulmonary vascular bed by lung 
destruction and fibrosis. 
• Hypoxemia and pulmonary vasculopathy can be 
contributory factors.  
• ILD is often associated with the collagen vascular dis.  
• A large number of patients have pulmonary fibrosis of 
unknown etiology.  
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• Patients are commonly older than 50 years 
and report an insidious onset of progressive 
dyspnea and cough for months to years.  
• It is uncommon for the mean PAP to exceed 
40 mmHg.  
• While none of the medical treatments 
developed for PAH have been shown to be 
effective in these patients, their use may 
worsen the hypoxemia. 
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Sleep-Disordered Breathing 
 
• The incidence of PH in the setting of 
obstructive sleep apnea, a common 
condition, appears to be <20% and is 
generally mild.  
• Some patients, present with severe PH in 
conjunction with sleep apnea, which may 
or may not be related.  
• sleep apnea and the PAH be treated as 
coexisting problems. 
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Alveolar Hypoventilation 
 
• PH can occur in patients with chronic 
hypoventilation and hypoxia secondary to 
thoracovertebral deformities.  
• Symptoms are slowly progressive and 
related to hypoxemia. 
• In patients with advanced disease, 
intermittent positive-pressure breathing 
and supplemental oxygen have been used 
successfully. 
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• PH secondary to hypoxemia has been 
reported in patients with neuromuscular 
disease as a result of generalized weakness 
of the respiratory muscles and in patients 
with diaphragmatic paralysis, generally a 
result of trauma to the phrenic nerve. 
  
• Nontraumatic bilateral diaphragmatic 
paralysis may go unrecognized until they 
present with either respiratory failure or PH. 
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GROUP IV 
PH Due to Thromboembolic Disease 
• Acute Pulmonary Thromboembolism 
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Chronic Thromboembolic Pulmonary Hypertension 
• Patients appropriately treated for acute 
pulmonary thromboembolism with IV  
heparin and chronic oral warfarin therapy 
usually do not develop chronic PH.  
• Some patients have impaired fibrinolytic 
resolution of the thromboembolism, which 
leads to organization and incomplete 
recanalization and chronic obstruction of 
the pulmonary vascular bed.  
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• Chronic thromboembolic PH has been well 
characterized and often mimics PAH. 
• In many patients, the initial pulmonary 
thromboembolism was undetected or untreated.  
• Many of these patients have underlying 
thrombophilic disorders, such as the lupus 
anticoagulant/anticardiolipin antibody 
syndrome, prothrombin gene mutation, or 
Factor V Leiden. 
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Diagnosis 
 
• The physical examination is typical of PH but may 
include bruits heard over areas of the lung, 
representing blood flow through vessels with partial 
occlusion.  
• A perfusion lung scan or contrast-enhanced spiral 
CT scan usually reveals multiple thromboemboli.  
• Pulmonary angiography is necessary to determine 
the precise location and proximal extent of the 
thromboemboli, and the potential for operability. 
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 Treatment 
• Thromboendarterectomy is an established 
surgical treatment in patients whose thrombi 
are accessible to surgical removal.  
• The operative mortality is fairly high, at ~12% 
in experienced centers.  
• Postoperative survivors who have a good 
result can expect to realize an improvement 
in functional class and exercise tolerance.  
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Sickle Cell Disease 
• Cardiovascular system abnormalities are 
prominent in the clinical spectrum of sickle cell 
disease, including PH.  
• The etiology is multifactorial, including 
hemolysis, impaired nitric oxide bioavailability, 
hypoxemia, thromboembolism, chronic high 
cardiac output, and chronic liver disease.  
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• Regardless of the mechanisms, the presence 
of PH in sickle cell disease is associated with 
a higher morbidity and mortality.  
• specific therapy appears to reduce the 
morbidity.  
• The use of drugs to treat PH is under clinical 
trials ,their efficacy remains unknown. 
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GROUP V 
Other Disorders Directly Affecting 
Pulmonary Vasculature 
• Sarcoidosis: 
• Can produce severe PH as a result of chronic 
severe fibrocystic lung involvement, or direct 
cardiovascular involvement.  
• There is a subset of sarcoidosis who present 
with severe PH believed to be due to direct 
pulmonary vascular involvement.  
• Many of these patients exhibit a favorable 
response to intravenous epoprostenol therapy. 
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Schistosomiasis 
 
• Although extremely rare in North America, 
schistosomiasis is the most common cause of 
PH worldwid. 
• The development of PH often occurs in the 
setting of hepatosplenic disease and portal 
hypertension.  
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• Schistosome ova can embolize from the liver 
to the lungs, where they result in an 
inflammatory pulmonary vascular reaction 
and chronic changes.  
• Diagnosis is confirmed by finding the parasite 
ova in the urine or stools of patients with 
symptoms, which can be difficult.  
• The efficacy of therapies directed toward PH 
in these patients is unknown. 
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HIV Infection 
 • The mechanism by which HIV infection 
produces PH remains unknown.  
• Although it is uncommon for HIV infection 
to result in PH, the marked rise in the 
prevalence of HIV infection worldwide 
could have a significant impact on the 
frequency that these entities are seen in 
combination. 
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• The evaluation and treatments are identical to 
those for IPAH.  
• Treatment of the HIV infection does not appear 
to affect the severity or natural history of the 
underlying PH. 
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